NCT07527390Not yet recruitingPhase 4
CANagliflozin In DIALysis Patients
Source: ClinicalTrials.gov · Last updated 6 May 2026
Brief summary (registry, in English)
Rationale: Sodium glucose co-transporter 2 (SGLT2) inhibitors are a relatively new class of drugs originally developed for the treatment of diabetes. Cardiovascular outcome trials with these drugs showed also beneficial effects of these agents on heart failure, cardiovascular disease and kidney outcomes. Secondary analyses from these trials demonstrated that these benefits were consistent in patients with or without type 2 diabetes and with or without chronic kidney disease (CKD) with a lower eGFR threshold of 20 mL/min/1.73m2. However, it is not yet clear if these drugs can also be used in patients with severe kidney disease who require dialysis. This is in part explained because SGLT2 inhibitors bind to a transporter which is located in the luminal side of proximal tubes in the kidney. If kidney function is low, and these patients have no or limited filtering capacity, it is possible that the efficacy of these drugs decrease. Notwithstanding, several animal experiments and preliminary clinical data have suggested that these drugs do have kidney and cardiac protective effects in case of severely decreased kidney function. The investigators hypothesize that SGLT2 inhibitors are distributed to several tissues in the body on top of the kidney and therefore the investigators would like to investigate the specific tissue distribution of SGLT2 inhibitors in patients on dialysis with-and without residual diuresis.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 7 Apr 2026
- Start date
- 1 Jun 2026
- Primary completion date
- 30 Jan 2027
- Lead sponsor
- University Medical Center Groningen
- Diseases
- Chronic kidney disease
- NCT number
- NCT07527390
- EU CT number
- 2025-522742-46-00
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 10
- From 1 Jun 2026 to the primary completion date, 30 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects on diuretics are allowed to participate but the dose should be stable for at least 4 weeks prior to screening
- Subjects already on a SGLT2 inhibitor are allowed to participate, but the drug should be inter-rupted 1 week prior to the first study day till the end of the second study day (as the half-life is 10-13 hours a wash-out of the study drug of at least 7-days should be considered)
- Active cardiovascular disease: myocardial infarction, angina pectoris, percutaneous translu-minal coronary angioplasty, coronary artery bypass grafting, stroke, or heart failure (NYHA I-IV) admission \< 3 months before inclusion
Other illness
- History of hypersensitivity to canagliflozin or another SGLT2 inhibitor
- Established peripheral arterial disease
- Patients with an active malignancy
Lab values
- History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by the laboratory assays conducted during the screening.
- Any medication, surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of medications including, but not limited to any of the following:
- Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection
- Gastro-intestinal ulcers and/or gastrointestinal or rectal bleeding within last six months
- Pancreatic injury or pancreatitis within the last six months
- Evidence of hepatic disease as determined by any one of the following: ALT or AST values exceeding 3x ULN at inclusion visit, a history of hepatic encephalopathy, a history of esophageal varices, or a history of portocaval shunt
- Use of rifampicin and cholestryramine
Age
- Subjects who participated in a trial with exposure to radiation before, are only allowed to participate if the total cumulative radiation burden in their life does not exceed 1 mSv per year, counting from the age of 18 years.
Other
- Mentally incapacitated subjects (i.e. not able to sign informed consent)
- Pregnant women and women of child-bearing potential who are not using reliable contraception
- Severe claustrophobia
- People using digoxin and/or lithium
Who the study is looking for
- Hemodialysis for more than 3 months (5 also with residual diuresis)
- Age ≥18 years of age
- Willing to sign informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitair Medisch Centrum Groningen Coordinator of this site? Confirm its status | Groningen | Netherlands | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.